Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.53 |
| ▸ | CDK4 | P11802 | 6/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021126 | 0.91 | CDK2 (0.53) | CDK2CDK4CDK1 | |
| SCHEMBL5102089 | 0.83 | CDK2 (0.76) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4024205 | 0.80 | CDK2 (0.56) | CDK2CDK4CDK1 | |
| SCHEMBL4030405 | 0.79 | CDK2 (0.63) | CDK2CDK4CDK1 | |
| SCHEMBL4020672 | 0.78 | CDK2 (0.54) | CDK2CDK4CDK1 | |
| SCHEMBL27533851 | 0.77 | CDK2 (0.81) | CDK2CDK4CDK1 | |
| SCHEMBL6603797 | 0.76 | CDK2 (0.46) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4025355 | 0.74 | CDK2 (0.64) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL5109334 | 0.74 | CDK2 (0.75) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6593149 | 0.70 | CDK2 (1.00) | CDK2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | CCNI, CDK3, CDK4 | CDK2 6/4885CDK4 3/4885CDK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.